Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs.
Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs.
复制标题
DOI：
10.1007/s10147-022-02163-3
复制
发表时间：
2022-06
影响因子：
3.3
通讯作者：
Matsumura N
中科院分区：
文献类型：
--
作者：
Nakai H;Matsumura N
随着聚腺苷二磷酸核糖聚合酶抑制剂的发展，晚期卵巢癌的治疗正在发生巨大的变化。这篇叙述性综述的目的是为基于日本目前使用的分子靶向药物的作用机制的晚期卵巢癌治疗的个体化提供方向。Paola-1研究显示，同源重组缺陷肿瘤患者在接受了完全手术和初次去髓手术并接受奥拉帕布和贝伐单抗治疗的患者中，无进展存活率非常好。Niraparib具有很高的肿瘤内渗透率，在PRIMA研究的亚组分析中，它对间歇性去瘤手术后残留肿瘤的患者最有效。这些数据表明在卵巢癌的治疗中实现完全手术和以治愈为目标的重要性，以及贝伐单抗、奥拉帕利布和尼拉帕利的使用应该如何个体化。
With the development of poly(ADP-ribose) polymerase inhibitors, the treatment of advanced ovarian cancer is changing dramatically. The purpose of this narrative review is to provide a direction for the individualization of advanced ovarian cancer treatment based on the mechanism of action of molecularly targeted drugs currently used in Japan. The PAOLA-1 study showed very good progression-free survival in patients with homologous recombination deficiency tumors who underwent complete surgery with primary debulking surgery and who received olaparib plus bevacizumab. Niraparib has high intratumor penetration, and in a subgroup analysis of the PRIMA study, it was most effective in patients with residual tumors after interval debulking surgery. These data suggest the importance of achieving complete surgery and aiming for cure in the treatment of ovarian cancer and how the use of bevacizumab, olaparib, and niraparib should be individualized.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-17-1327
发表时间：
2018-02-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Norquist BM;Brady MF;Harrell MI;Walsh T;Lee MK;Gulsuner S;Bernards SS;Casadei S;Burger RA;Tewari KS;Backes F;Mannel RS;Glaser G;Bailey C;Rubin S;Soper J;Lankes HA;Ramirez NC;King MC;Birrer MJ;Swisher EM
通讯作者：
Swisher EM
基于肿瘤微环境的癌细胞杀伤的背景综合致死率。
影响因子：
11.2
作者：
Chan N;Pires IM;Bencokova Z;Coackley C;Luoto KR;Bhogal N;Lakshman M;Gottipati P;Oliver FJ;Helleday T;Hammond EM;Bristow RG
通讯作者：
Bristow RG
影响因子：
45.3
作者：
DiSilvestro, Paul;Colombo, Nicoletta;Moore, Kathleen N.
通讯作者：
Moore, Kathleen N.
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.
影响因子：
51.1
作者：
Banerjee, Susana;Moore, Kathleen N.;DiSilvestro, Paul
通讯作者：
DiSilvestro, Paul